+34 679 490 537info@nanbiosis.com

Posts Taged biomarkers

Open call for contribution to the Special Issue by MDPI in IJMS about “In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours”

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25 NMR: Biomedical Applications I Unit (from CIBER-BBN and Autonomous University of Barcelona), is the Guest Editor of a special issue launched by MDPI in the International Journal of Molecular Sciences (IF 4.183). This special issue is about In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours

Contributions with papers or reviews to this issue, can be fowarded to the Guest Editor (AnaPaula.Candiota@uab.cat) with a tentative title and/or abstract.

Final deadline for submission: 31/10/2020

Read More

NANBIOSIS U2, U3 & U29 participate in the POC4CoV project to develop diagnostic technologies for SARS-COV-2

The Spanish Higher Council for Scientific Research (CSIC) will finance the project Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV), whose objective is to have effective diagnostic technologies for Covid-19. The Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and the Institute of Materials Science of Aragon (ICMA) participate in it.

The POC4CoV project aims to develop Point-of-Care (POC) devices for the in vitro diagnosis of SARS-COV-2 infection quickly and reliably, thanks to the use of multiplexed systems and the use of particular biomolecular probes. To do this, POC technological platforms will be used in combination with specific capture biomolecules and nanobiotechnological probes (enzyme bioconjugates and biofunctional plasmonic and magnetic nanoparticles), which will allow the simultaneous detection of different biomarkers (viral RNA and antigens, IgM and IgG) related to Covid-19 disease. The biomolecular complexes will be collected at specific points on the devices where the electrochemical or optical signals will be recorded.

The developed POC platforms will undergo analytical and clinical validation in a clinical setting.

Three units of NANBIOSIS (form CIBER-BBN and IQAC-CSIC) will will take an active participation in the project.

NANBIOSIS Unit 2 Custom Antibody Service (CAbS), will produce antibodies against the Spike protein and other virus proteins, trying to maximize the recognition of those epitopes that differentiate SARS-CoV-2 from other Coronaviruses

NANBIOSIS Unit 3 Synthesis of Peptides Unit will synthesize peptidic sequences that will allow to identify towards which epitopes the immune response is directed, which will allow to develop more specific diagnostic methods.

NANBIOSIS Unit 29 Oligonucleotide Synthesis Platform (OSP) has designed probes with oligonucleotide sequences that will allow the capture of viral RNA through the formation of high affinity triplex complexes

Read More

Infertility: Exosomal microRNAs in seminal plasma as sensitive and specific biomarkers of the presence of testicular spermatozoa for azoospermia

NANBIOSIS ICTS coordination equipment has recently received from researchers of Human Molecular Genetics Group of Bellvitge Biomedical Research Institute (IDIBELL) a publication mentioning NANBIOSIS in the Acknowledgements for its participation in the results of its investigations. The article has been publish by the journal Human Reproduction of OXFORD UNIV PRESS  with Quartile 1/ Decile 1.

The study carried out by  Maria Barcelo, Ana Mata, Lluís Bassas, and Sara Larriba demonstrates the potential of several miRNAs contained in small extracellular vesicles (sEVs) of seminal fluid as sensitive and specific biomarkers for selecting those azoospermic individuals with real chances of obtaining spermatozoa from the testicular biopsy. The nanoparticle tracking analysis was performed by the ICTS NANBIOSIS  U6 Biomaterial Processing and Nanostructuring Unit.

Article of reference:

Maria Barceló, Ana Mata, Lluís Bassas and Sara Larriba, Exosomal microRNAs in seminal plasma are markers of the origin of azoospermia and can predict the presence of sperm in testicular tissue Human Reproduction, pp. 1–12, 2018doi:10.1093/humrep/dey072

Read More

NANBIOSIS resarchers in CCMIJU identify biomarkers for bridging the gap between preclinical studies in large animal models and clinical trials

Researchers of NANBIOSIS Units at CCMIJU have publish a very relevant article about the studies on  hematological, biochemical and immunological parameters, as well as magnetic resonance derived cardiac function measurements obtained from a swine myocardial infarction model that allows to predict the severity of myocardial infarction in a clinically relevant animal model providing a  simple, affordable and reliable way that could prove useful in the follow up of myocardial infarction and in the evaluation of new therapeutic strategies in this animal model.

Biochemical and hematological determinations were performed by the ICTS Nanbiosis (Unit 19. Clinical test lab at CCMIJU). Flow cytometry analyses were performed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Blood sampling and maintenance of animals were performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). Myocardial infarction induction and Magnetic Resonance studies waere performed by the ICTS Nanbiosis (Unit 21. Experimental operating rooms and Unit 24. Medical imaging at CCMIJU).

Article of reference: “Altered hematological, biochemical and immunological parameters as predictive biomarkers of severity in experimental myocardial infarction” DOI: https://doi.org/10.1016/j.vetimm.2018.10.007

 

Read More

NANBIOSIS at the EATRIS Conference Translational Medicine 2017

NANBIOSIS  has actively participated in the third bi-annual conference organised by EATRIS, (the European infrastructure for translational medicine) in Prague on 24-26 of September Translational Medicine 2017: Enhancing predictivity in medicines development . The event gathered a wide range of stakeholders (industry, academia, policymakers) and focussed on bringing together the latest approaches to increase chances of success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.

Jesús Izco, Coordinator of NANBIOSIS, presented NANBIOSIS initiatives of joint collaboration, which were well received and will be coordinated and developed during the next months.

Read More